Opthea to Present Sozinibercept Data at EURETINA Congress
Ticker: OPTEY · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-data, ophthalmology, drug-development
TL;DR
Opthea presenting key data on sozinibercept at EURETINA - big deal for wet AMD/DME drug.
AI Summary
Opthea Limited announced on September 18, 2024, that it will have a significant presence at the 24th EURETINA Congress and EURETINA Innovation Spotlight. The company will present data on its novel biologic therapy, sozinibercept, for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This participation highlights Opthea's ongoing clinical development and potential commercialization efforts for its lead drug candidate.
Why It Matters
Opthea's presentation at a major ophthalmology congress could generate significant interest from clinicians and investors, potentially impacting the company's valuation and future partnerships.
Risk Assessment
Risk Level: medium — The company is presenting clinical data, which could be positive or negative, and is still in the development phase, indicating inherent risks in drug commercialization.
Key Players & Entities
- Opthea Limited (company) — Registrant
- sozinibercept (drug) — Lead drug candidate
- 24th EURETINA Congress (event) — Conference where data will be presented
- EURETINA Innovation Spotlight (event) — Conference where data will be presented
- wet age-related macular degeneration (AMD) (disease) — Indication for sozinibercept
- diabetic macular edema (DME) (disease) — Indication for sozinibercept
FAQ
What specific data will Opthea present at the 24th EURETINA Congress?
The filing indicates Opthea will present data on its novel biologic therapy, sozinibercept, for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), but does not specify the exact data points.
When is the 24th EURETINA Congress scheduled to take place?
The filing does not specify the exact dates for the 24th EURETINA Congress, only that Opthea will have a presence during the month of September 2024.
What is the primary indication for Opthea's drug, sozinibercept?
Sozinibercept is being developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
What is the filing type and date?
This is a Form 6-K filed on September 18, 2024.
Where is Opthea Limited headquartered?
Opthea Limited is headquartered in South Yarra, Victoria, Australia.
Filing Stats: 156 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-09-18 06:05:43
Filing Documents
- opt_announces_completion.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 21KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-107588.txt ( ) — 213KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 09/18/2024